Participated · Equity · Aug 2023

COMPASS Pathways develops COMP360, a proprietary synthetic psilocybin formulation delivered with psychological support to treat individuals who do not respond to current therapies. The company has earned FDA Breakthrough Therapy status and the UK ILAP designation for COMP360 in treatment‑resistant depression (TRD). It completed a phase 2b study showing significant symptom improvement with a 25mg dose and has launched the largest‑ever randomized, controlled, double‑blind phase 3 programme for TRD. COMPASS is also running phase 2 trials in PTSD and anorexia nervosa and investing in digital technology to support its therapy. The company announced a large private financing to support its clinical programmes, commercial planning and research through roughly late 2025. Compass Pathways is a London-based mental health care company focused on developing psilocybin therapy for treatment-resistant depression. Its lead program is a large-scale psilocybin therapy clinical trial being conducted at 20 sites across nine countries in Europe and North America. The company received FDA Breakthrough Therapy designation for its psilocybin therapy program in 2018. Compass intends to use the Series B proceeds to expand its lead program, support research into additional indications for psilocybin therapy, advance its preclinical pipeline, develop digital technologies, and establish new academic and clinical research partnerships. Leadership includes CEO and co-founder George Goldsmith and President, Chief Business Officer and co-founder Lars Wilde.